Rivoceranib (Apatinib, YN968D1) is an orally bioavailable experimental drug candidate being developed outside of China by Elevar Therapeutics, for the treatment of solid tumors including advanced or metastatic gastric cancer, colorectal cancer, hepatocellular carcinoma, and adenoid cystic carcinoma.
Rivoceranib (Apatinib, YN968D1) ass en oral bioavailable experimentellen Drogenkandidat, deen ausserhalb China vun LSK BioPharma entwéckelt gëtt, fir d'Behandlung vu festen Tumoren inklusive fortgeschrittenem oder metastaseschen Magenkrees, Darmkrebs a hepatozellulären Karzinom.